My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

12.15 -0.22 (-1.78%)

Delayed Quote Updated: 2:51 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Could This Cathie Wood Stock Soar in 2027? ↗

September 27, 2026

This biotech has grabbed plenty of headlines recently.

Via The Motley Fool

Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances ↗

September 19, 2026

Intellia Therapeutics (NASDAQ:NTLA) executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company’s ongoing Phase III program in...

Via MarketBeat

Topics Intellectual Property

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

August 31, 2026

Ark Invest was a buyer of tech stocks down as much as 53% from their recent all-time highs.

Via The Motley Fool

Topics ETFs

Intellia Therapeutics (NASDAQ:NTLA) Slips on Q2 Revenue Miss Despite In-Line Loss ↗

August 06, 2026

Via Chartmill

Intellia Therapeutics Inc (NASDAQ:NTLA) Reports Strong Q4 2025 Revenue Beat and Confirms Key 2026 Pipeline Milestones ↗

February 26, 2026

Via Chartmill

Intellia (NTLA) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Lonvo-z Phase III trial met primary endpoint with 87% attack reduction versus placebo.

Via The Motley Fool

Topics Earnings

Intellia Therapeutics Q2 Earnings Call Highlights ↗

August 07, 2026

Intellia Therapeutics (NASDAQ:NTLA) said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the...

Via MarketBeat

Topics Earnings Intellectual Property

A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗

July 08, 2026

This new technology could one day significantly expand the market for gene-editing biotechs.

Via The Motley Fool

Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% ↗

July 01, 2026

It might pull it off, provided several things fall right in place.

Via The Motley Fool

Wall Street Expects This Growth Stock That's Already Climbed 70% to Almost Double -- And Here's Why. ↗

June 24, 2026

This biotech player is heading for a critical moment.

Via The Motley Fool

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026? ↗

June 20, 2026

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare.

Via The Motley Fool

This Stock Is Up 58% This Year. Is It too Late to Buy? ↗

June 17, 2026

There could be additional catalysts for this drugmaker over the next year.

Via The Motley Fool

1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't ↗

June 03, 2026

This particular sector may suit cautious and aggressive investors.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

May 06, 2026

One of these stocks plummeted 49% on Tuesday.

Via The Motley Fool

Topics Initial Public Offering

3 Biotech Stocks That Could Benefit from the Patent Cliff ↗

April 27, 2026

Via MarketBeat

Topics Intellectual Property

Top movers in Friday's after hours session ↗

April 24, 2026

Via Chartmill

2 Healthcare Stocks to Buy and 1 to Approach With Caution ↗

April 15, 2026

Recent performances don't tell the whole story.

Via The Motley Fool

This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy? ↗

March 08, 2026

This run could be short-lived.

Via The Motley Fool

Topics Death

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

March 03, 2026

The growth investor kicked off this week by buying up some hard-hit stocks.

Via The Motley Fool

Why Did NTLA Stock Jump 10% In Pre-Market Today? ↗

March 02, 2026

The company announced that the U.S. FDA lifted a clinical hold on its Phase 3 trial of ATTR-CM treatment drug.

Via Stocktwits

Intellia (NTLA) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

Intellia (NTLA) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy? ↗

February 07, 2026

Will this biotech's innovative platform finally pay off?

Via The Motley Fool

NTLA Stock Jumped 13% Today – What Is The Latest FDA Action All About? ↗

January 27, 2026

The U.S. Food and Drug Administration lifted the clinical hold on a Phase 3 Trial, which was imposed on October 29, 2025 following the observation of Grade 4 liver transaminases and increased total...

Via Stocktwits

Nasdaq, S&P 500 Futures Edge Higher Ahead Of Long Weekend: Why NVDA, MU, NTLA, ASTS Are On Traders' Radar Today ↗

January 16, 2026

Via Stocktwits

Topics Stocks

Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD ↗

January 16, 2026

ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October.

Via Stocktwits

Topics Artificial Intelligence ETFs

Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares ↗

January 12, 2026

Focused on CRISPR-based therapies for rare diseases and oncology, this biotech just reported a notable insider sale in public filings.

Via The Motley Fool

Topics Regulatory Compliance

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street ↗

December 29, 2025

Don't get too excited about their prospects.

Via The Motley Fool

Topics Death

How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗

December 02, 2025

Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam.

Via Investor's Business Daily

Intellia (NTLA) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Intellia (NTLA) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.